Clinical Study Shows Regenecare(R) Relieves Pain and Itching of Skin Rashes Caused By Widely Used Cancer Drugs
Posted on: Wednesday, 11 July 2007, 15:04 CDT
The Journal of the American Society of Clinical Oncology has published the early results of a clinical study conducted by Dr. Siu-Fun Wong, and her colleagues, which concluded that the topical gel, Regenecare®, caused a statistically significant reduction in the pain and itching of a rash that results from the use of anti-cancer drugs known as EGFR inhibitors. This ongoing supportive care trial is listed on the National Cancer Institute Clinical Trials website (www.cancer.gov).
Paul Miller, President of MPM Medical, stated, "EGFR inhibitors form a group of drugs, sold by several pharmaceutical companies, which are effective in the treatment of cancer. However, after a few weeks of use, an acne-like rash often appears on the face, neck, back, hands, and/or legs resulting in severe pain and itching for the patient. We know of no other evidence-based topical applications reported in the scientific literature shown to help manage rash symptoms caused by EGFR drugs."
Regenecare® is a proprietary product of MPM Medical, Inc., a wholly owned subsidiary of RBC Life Sciences, Inc. (OTCBB:RBCL).
MPM Medical develops and markets a line of prescription and nonprescription products for wound management, through medical-surgical dealers, to nursing homes, hospitals, and cancer clinics.
The statements above, other than statements of historical facts, may be forward-looking. Actual events will be dependent upon a number of factors and risks including but not limited to changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.
Source: Business Wire
Related Articles
- Addario Lung Cancer Medical Institute Announces Diagnostic Screening and Clinical Research Collaborations With Response Genetics, Inc.
- Orthopaedic Surgeon Kevin Smith, MD, Joins Northwest Hospital & Medical Center and The Sports Medicine Clinic
- Despite Tight Financial Market, Company With Anti-Cancer Drug in Clinical Trial Raises $3.6 Million in Private Placement
- Video: The Looming Crisis in Cancer Drug Development: 97% of Adult Cancer Patients Do Not Take Advantage of Clinical Trial Programs
- Dr. Howard Epstein Joins Blue Cross As Medical Director for Commercial Operations and Clinical Design
- Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
- Research and Markets: Recent Changes To Medicare's Drug Reimbursement Policies Have Drastically Altered The Way Treatment Is Financed And Promise To Shape The Future Of Cancer Treatment In The United States
- Community Oncology Alliance Refutes NBC Nightly News Story 'Cancer Docs Profit From Chemotherapy Drugs'
- Medical Center to Host Flu Shot Clinic
- U-Turn Allows Cancer Patients to Get New Drug
 |
 |
User Comments (0)
RSS Feeds